Human Tuberculosis Vaccine Market, By Type (Live attenuated vaccine, Inactivated, and Others), By Age Group (Pediatrics and Adults), By Distribution Channel (Private and Public), By Geography (North America, Latin America, Asia Pacific, Europe, Middle East, and Africa)

Published In : Nov 2024

Code : CMI5209

Pages :197

Formats :

Excel and PDF

Industry : Pharmaceutical

Regional Analysis

Human Tuberculosis Vaccine Market Regional Insights

To learn more about this report, request sample copy

Dominating Region: Asia Pacific

Asia Pacific is expected to dominate the human tuberculosis vaccine sector with the highest market share of 36.8% in 2024, owing to significant burden of tuberculosis, with countries like India and China accounting for a large percentage of global cases.

Fastest-Growing Region: Africa

The Africa region exhibits the fastest growth with an estimated 22.7% market share in 2024. This is due to increased government funding and initiatives aimed at enhancing vaccination coverage, which is driving the demand for TB vaccines.

Human Tuberculosis Vaccine Market Outlook for Key Countries

U.S.’ increasing R&D investments and collaborations

The U.S. human tuberculosis vaccine industry is driven by increasing investments in research and development, alongside collaborations between government entities and industry leaders. These partnerships aim to accelerate the development of new vaccines, addressing the urgent need for effective TB prevention strategies amid rising incidence rates and drug-resistant strains.

China’s strong government funding

China human tuberculosis vaccine sector is supported by strong government funding and its status as one of the top TB-burdened nations. Significant investments in public health initiatives aim to enhance vaccination coverage, addressing the high prevalence of tuberculosis. This proactive approach facilitates access to vaccines, driving demand and improving community health outcomes.

India’s collaboration with global stakeholders to accelerate the introduction of new vaccines

India continues to face a significant disease burden, particularly from tuberculosis. The government is collaborating with global stakeholders to accelerate the introduction of new vaccines, aiming to enhance public health outcomes and reduce mortality rates associated with this infectious disease.

Japan’s research and development activities

Japan human tuberculosis vaccine industry is significantly shaped by domestic players dedicated to advancing innovative vaccine technologies. Companies like Japan BCG Laboratory are at the forefront, striving to enhance public health and effectively combat tuberculosis and other infectious diseases.